Payment overview · 2025
General Payments
$668.33
39 reported records · 12 companies
Healthcare provider profile · identity verified
David Brian Drury, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PELHAM, GA · NPI 1124093380
Verified facts
What the public records show
CMS Open Payments records show David Brian Drury, M.D. received $668.33 in general payments during 2025 across 39 reported records.
Lilly USA, LLC accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 303 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.45 | 22.5% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.11 | 20.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $89.95 | 13.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.67 | 11.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.47 | 7.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.84 | 6.1% | 2 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $32.92 | 4.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.56 | 4.3% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.08 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.12 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.31 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.85 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $668.33 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.45 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.11 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $134.13 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $74.95 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.47 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.13 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.13 | 2 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $32.92 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.08 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 303 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 377 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 106 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 140 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
303 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
377 | 72 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
377 | 72 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
154 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
140 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1314 | 294 |
| Amlodipine Besylate | Amlodipine Besylate | 1149 | 268 |
| Potassium Chloride | Potassium Chloride | 684 | 134 |
| Gabapentin | Gabapentin | 560 | 121 |
| Lisinopril | Lisinopril | 516 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 465 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 94 |
| Furosemide | Furosemide | 423 | 95 |
| Metformin Hcl Er | Metformin Hcl | 418 | 99 |
| Losartan Potassium | Losartan Potassium | 382 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 80 |
| Jardiance | Empagliflozin | 377 | 72 |
| Trazodone Hcl | Trazodone Hcl | 361 | 67 |
| Fluticasone Propionate | Fluticasone Propionate | 346 | 117 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 311 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 76 |
| Farxiga | Dapagliflozin Propanediol | 303 | 50 |
| Omeprazole | Omeprazole | 280 | 71 |
| Carvedilol | Carvedilol | 276 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 274 | 64 |
| Famotidine | Famotidine | 244 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 240 | 54 |
| Allopurinol | Allopurinol | 231 | 48 |
| Eliquis | Apixaban | 228 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 50 |
| Metformin Hcl | Metformin Hcl | 204 | 49 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 199 | 54 |
| Prednisone | Prednisone | 197 | 105 |
| Citalopram Hbr | Citalopram Hydrobromide | 190 | 41 |
| Donepezil Hcl | Donepezil Hcl | 185 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 185 | 34 |
| Tramadol Hcl | Tramadol Hcl | 170 | 34 |
| Mirtazapine | Mirtazapine | 165 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 165 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 41 |
| Trulicity | Dulaglutide | 154 | 26 |
| Glipizide | Glipizide | 147 | 33 |
| Montelukast Sodium | Montelukast Sodium | 146 | 33 |
| Rybelsus | Semaglutide | 140 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 135 | 30 |
| Celecoxib | Celecoxib | 134 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 36 |
| Alendronate Sodium | Alendronate Sodium | 126 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 126 | 27 |
| Pregabalin | Pregabalin | 124 | 23 |
| Chlorthalidone | Chlorthalidone | 122 | 33 |
| Clonazepam | Clonazepam | 122 | 20 |
| Ozempic | Semaglutide | 119 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 117 | 21 |
| Colchicine | Colchicine | 111 | 25 |
| Meclizine Hcl | Meclizine Hcl | 108 | 24 |
| Mounjaro | Tirzepatide | 106 | 16 |
| Valsartan | Valsartan | 106 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 104 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 21 |
| Simvastatin | Simvastatin | 97 | 24 |
| Meloxicam | Meloxicam | 95 | 30 |
| Torsemide | Torsemide | 93 | 22 |
| Buspirone Hcl | Buspirone Hcl | 92 | 16 |
| Alprazolam | Alprazolam | 91 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 21 |
| Methylprednisolone | Methylprednisolone | 90 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 20 |
| Ondansetron Odt | Ondansetron | 90 | 38 |
| Fluconazole | Fluconazole | 88 | 40 |
| Baclofen | Baclofen | 86 | 21 |
| Januvia | Sitagliptin Phosphate | 80 | 13 |
| Indapamide | Indapamide | 79 | 15 |
| Levemir Flexpen | Insulin Detemir | 79 | 16 |
| Promethazine Hcl | Promethazine Hcl | 79 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 77 | 11 |
| Sertraline Hcl | Sertraline Hcl | 77 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 40 |
| Spironolactone | Spironolactone | 70 | 15 |
| Bupropion Xl | Bupropion Hcl | 69 | 17 |
| Ezetimibe | Ezetimibe | 69 | 22 |
| Clonidine Hcl | Clonidine Hcl | 67 | 13 |
| Lorazepam | Lorazepam | 66 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 61 | 13 |
| Benazepril Hcl | Benazepril Hcl | 61 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 18 |
| Nifedipine Er | Nifedipine | 59 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 17 |
| Linzess | Linaclotide | 58 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 12 |
| Xarelto | Rivaroxaban | 55 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 15 |
| Naproxen | Naproxen | 54 | 18 |
| Amoxicillin | Amoxicillin | 52 | 32 |
| Finasteride | Finasteride | 52 | 12 |
| Irbesartan | Irbesartan | 52 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Azithromycin | Azithromycin | 50 | 38 |
| Ibuprofen | Ibuprofen | 50 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 49 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 12 |
| Synthroid | Levothyroxine Sodium | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 37 |
| Azelastine Hcl | Azelastine Hcl | 45 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Atenolol | Atenolol | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Nystatin | Nystatin | 42 | 21 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 39 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Risperidone | Risperidone | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Levemir | Insulin Detemir | 33 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 32 | 11 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | 11 |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Prolia | Denosumab | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Etodolac | Etodolac | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 11 |
| Estradiol | Estradiol | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $668.33 · 39 records | Lilly USA, LLC | AFFINITY, AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, EVENITY, FARXIGA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error